Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2008
Event: Entry into a Material Definitive Agreement with the U.S. Department of Health and Human Services (HHS).
Key Financial Metrics and Contract Details
- Contract Value: Maximum potential payment of $404 million.
- Product Volume: Up to 14.5 million doses of BioThrax (Anthrax Vaccine Adsorbed).
- Price Range: Total purchase price estimated between $362.7 million and $402.8 million, contingent on product shelf-life dating.
- Shipping Revenue: Approximately $1.9 million for shipping services.
- Contract Term: September 30, 2008, through September 30, 2011.
- Delivery Schedule: Commencing September 2009, following the completion of a prior 18.75 million dose contract.
Material Changes and Funding Status
This filing represents a new material agreement rather than a change in historical financial performance. Key funding details include:
- Funded Amount: Funds for the first 5.7 million doses are currently committed.
- Unfunded Amount: Procurement of the remaining 8.8 million doses is subject to the annual appropriations process for the Strategic National Stockpile (SNS).
- Pricing Variable: Final revenue depends on FDA approval to extend BioThrax shelf life from three to four years. Four-year dated product commands a higher price than three-year dated product.
Outlook, Risks, and Contingencies
- Regulatory Contingency: Revenue realization is partially dependent on FDA approval of a biologics license application supplement to extend shelf life.
- Appropriation Risk: The full contract value is not guaranteed; the remaining 8.8 million doses require future congressional appropriations.
- Operational Timing: Deliveries are scheduled to begin in September 2009, creating a gap between the agreement date and revenue recognition.
Investor Verification Checklist
- Verify the status of the FDA application to extend BioThrax shelf life to four years.
- Monitor U.S. government appropriations for the Strategic National Stockpile to confirm funding for the remaining 8.8 million doses.
- Review the completion status of the current 18.75 million dose supply contract to ensure on-time transition to the new agreement.
- Assess the impact of the $404 million potential revenue on future cash flow projections given the 2009 start date.